Treatment of Periodontal Intra-bony Defects With a Volume Stable Collagen Matrix or Deproteinized Bovine Bone Mineral With 10% Collagen
Treatment of Periodontal Intra-bony Defects With a Volume Stable Collagen Matrix or Deproteinized Bovine Bone Mineral With 10% Collagen. A 12-month Multi-center Randomized Controlled Trial
University of Bern
80 participants
Sep 1, 2025
INTERVENTIONAL
Conditions
Summary
To compare the healing of intrabony periodontal defects treated with either open flap debridement and a volume-stable collagen matrix (VCMX) or a deproteinized bovine bone mineral with 10% collagen. The results will shed light on the clinical potential of VCMX in regenerative periodontal surgery and help to develop new treatment strategies.
Eligibility
Inclusion Criteria6
- Patients with localized or generalized periodontitis Stage III and Stage IV, Grade A-B-C
- Males and females
- Age at least 18 years and older
- Presence of interdental intra-bony defects (I, II and III walls) in either the maxilla or the mandible with a PD ≥ 6 mm
- Defects with an intra-bony component \> 3 mm for both groups
- Intra-bony defect located only at one aspect (mesial or distal)
Exclusion Criteria10
- Patients with systemic disease that could interfere with periodontal wound healing
- Prolonged antibiotic treatment or anti-inflammatory treatment within 4 weeks prior to surgery
- Pregnant or lactating
- Smokers with \> 10 cig./day
- Patients with FMPS and FMBS \> 25 % after completion of non-surgical periodontal therapy
- Multi-rooted teeth with furcation involvement
- Third molars
- Teeth with circumferential defects
- Interdental craters
- Written Informed Consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Infrabony defects will be filled with a volume-stable collagen matrix
Infrabony defects will be filled with with a deproteinized bovine bone mineral with 10% collagen
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06676826